OptimICE-pCR trial: what clinicians have said so far
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- NCT05812807 ↗
- Recruiting
- Alliance for Clinical Trials in Oncology
- Deep size, estimated: 301+ verified statements once built
We haven't built an HCP commentary report on OptimICE-pCR (early-stage triple-negative breast cancer with pathologic complete response; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 23 indexed sources
Automated from all 23 indexed sources (Apr 2022 – Jul 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether observation can replace adjuvant pembrolizumab after pCR to neoadjuvant chemotherapy plus pembrolizumab without losing benefit
- Whether omitting adjuvant pembrolizumab spares immune-related adverse events such as adrenal insufficiency and hypophysitis
- Which patients with pCR can safely omit adjuvant pembrolizumab, and whether MRD or ctDNA testing should guide it
Indexed commentary on OptimICE-pCR so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 17 posts on X, typically up to 75 once built | |
| 4 podcast episodes, typically up to 18 once built | |
| 2 YouTube videos, typically up to 9 once built |
The trial
ClinicalTrials.gov- Official title
- OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8; Early Stage Triple-Negative Breast Carcinoma; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8
- Interventions
- Pembrolizumab; Patient Observation; Biopsy; Biospecimen Collection; Questionnaire Administration; Quality-of-Life Assessment
- Arms
- Arm I (pembrolizumab) · Active comparator
- Arm II (observation) · Experimental
- Enrollment
- 1,295 (estimated)
- Primary outcomes
- Recurrence-free survival (RFS)
- Sponsor
- Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI)
- Start
- Jun 14, 2023
- Primary completion
- May 31, 2033 (estimated)
- Results posted
- No
- Registry record
- NCT05812807 · updated Aug 5, 2026